Drugsupdate.com is up for sale. To own one of the most recognized online brands by doctors in India with millions of visitors - click here.

logo image
news images

FDA Approves Brilinta (ticagrelor); AstraZeneca

28-Nov-2011

 

For the reduction of thrombotic events in patients with acute coronary syndrome, by Astrazeneca; Approved July 2011

 

General Information

Brilinta (ticagrelor) is a reversibly binding oral adenosine diphosphate (ADP) receptor antagonist. It selectively inhibits P2Y12, a key target receptor for ADP. ADP receptor blockade inhibits the action of platelets in the blood, reducing recurrent thrombotic events.

Brilinta is specifically indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).

Brilinta is supplied as a tablet for oral administration. The recommended initial dose is 180 mg (two 90 mg tablets) loading dose and continue treatment with 90 mg twice daily. After the initial loading dose of aspirin (usually 325 mg), use Brilinta with a daily maintenance dose of aspirin of 75-100 mg.

 

Side Effects

Adverse events associated with the use of Brilinta may include, but are not limited to, the following:

bleeding

dyspnea


Mechanism of Action

Brilinta (ticagrelor) is a cyclopentyltriazolopyrimidine and inhibits platelet activation and aggregation mediated by the P2Y12 ADP-receptor

© 2011-2019 DrugsUpdate.com. Disclaimer | Site Map

Feedback
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.